Intelligent Bio Solutions Raises $3.8M Through Warrant Deals

Intelligent Bio Solutions ( (INBS) ) has provided an update.

On July 25, 2025, Intelligent Bio Solutions Inc. entered into inducement agreements with existing warrant holders to raise approximately $3.8 million in gross proceeds. The agreements involve the exercise or prepayment of Series G and Series H-1 warrants at a reduced price, with the issuance of new Series J warrants. The proceeds will fund the completion of the company’s 510k filing with the U.S. FDA for its Fingerprint Drug Screening System and support working capital and general corporate purposes. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the transaction, which is expected to close around July 28, 2025.

Spark’s Take on INBS Stock

According to Spark, TipRanks’ AI Analyst, INBS is a Neutral.

The overall stock score is buoyed by positive corporate events that promise future growth and market expansion. However, the score is tempered by ongoing financial challenges, particularly in profitability and cash flow. Technical signals offer a mixed outlook, and valuation metrics are currently unattractive due to negative earnings.

To see Spark’s full report on INBS stock, click here.

More about Intelligent Bio Solutions

Intelligent Bio Solutions Inc. is a medical technology company specializing in intelligent, rapid, non-invasive testing solutions. The company focuses on its Intelligent Fingerprinting Drug Screening System, which analyzes fingerprint sweat to detect recent drug use, including opiates, cocaine, methamphetamine, and cannabis. This system is designed for use in safety-critical industries such as construction, manufacturing, engineering, transport, logistics, mining, drug treatment organizations, and coroners.

Average Trading Volume: 180,680

Technical Sentiment Signal: Strong Sell

Current Market Cap: $11.13M

For detailed information about INBS stock, go to TipRanks’ Stock Analysis page.